Old API Wind-down Ltd. Stock

Stocks

ARLZQ

CA03852X1006

Pharmaceuticals

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Old API Wind-down Ltd. -.--% -
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Old API Wind-down Ltd.

Market Cap 87.35K 76.11K 70.16K 65.99K 123K 8.23M 124K 835K 324K 4.06M 328K 321K 14.06M P/E 2016
-2.53x
P/E 2017 -0.75x
Enterprise Value 246M 214M 197M 186M 347M 23.16B 350M 2.35B 912M 11.41B 922M 903M 39.56B EV / Sales 2016
9.18x
EV / Sales 2017 3.22x
Free-Float
100%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+32.62%-5.37%+39.94%+145.38% 980B
-3.20%-4.17%+51.52%+39.07% 550B
-2.14%-3.68%+16.71%+56.15% 382B
-1.75%+0.25%+25.86%+16.53% 317B
+0.39%-1.83%+25.24%+13.47% 270B
+0.64%-2.70%+24.76%+30.74% 269B
+4.59%+1.98%-40.02%-45.89% 191B
-1.90%-4.65%+16.56%+47.00% 182B
-1.35%-1.68%+14.59%+56.94% 154B
Average -0.45%-2.41%+19.46%+39.93% 329.4B
Weighted average by Cap. -0.97%-3.38%+28.28%+64.08%

Financials

2016 2017
Net sales 54.27M 47.29M 43.59M 41M 76.7M 5.11B 77.24M 519M 201M 2.52B 204M 199M 8.74B 106M 92.31M 85.1M 80.04M 150M 9.99B 151M 1.01B 393M 4.92B 398M 389M 17.06B
Net income -103M -89.72M -82.71M -77.8M -146M -9.71B -147M -984M -382M -4.78B -387M -378M -16.58B -125M -109M -101M -94.59M -177M -11.8B -178M -1.2B -465M -5.82B -470M -460M -20.16B
Net Debt 209M 183M 168M 158M 296M 19.74B 298M 2B 777M 9.73B 786M 770M 33.73B 246M 214M 197M 186M 347M 23.15B 350M 2.35B 912M 11.41B 922M 902M 39.55B
Logo Old API Wind-down Ltd.
Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Employees
-
  1. Stock Market
  2. Stocks
  3. ARLZQ Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!